etal muscle Na ϩ -K ϩ -2Cl Ϫ cotransporter (NKCC) activity provides a potential mechanism for regulated K ϩ uptake. ␤-Adrenergic receptor (␤-AR) activation stimulates skeletal muscle NKCC activity in a MAPK pathway-dependent manner. We examined potential G protein-coupled pathways for ␤-AR-stimulated NKCC activity. Inhibition of G s-coupled PKA blocked isoproterenol-stimulated NKCC activity in both the slow-twitch soleus muscle and the fast-twitch plantaris muscle. However, the PKA-activating agents cholera toxin, forskolin, and 8-bromo-cAMP (8-BrcAMP) were not sufficient to activate NKCC in the plantaris and partially stimulated NKCC activity in the soleus. Isoproterenol-stimulated NKCC activity in the soleus was abolished by pretreatment with pertussis toxin (PTX), indicating a G i-coupled mechanism. PTX did not affect the 8-BrcAMP-stimulated NKCC activity. PTX treatment also precluded the isoproterenol-mediated ERK1/2 MAPK phosphorylation in the soleus, consistent with NKCC's MAPK dependency. Inhibition of isoproterenolstimulated ERK activity by PTX treatment was associated with an increase in Akt activation and phosphorylation of Raf-1 on the inhibitory residue Ser 259 . These results demonstrate a novel, muscle phenotype-dependent mechanism for ␤-AR-mediated NKCC activation that involves both G s and G i protein-coupled mechanisms. potassium; mitogen-activated protein kinases; protein kinase A; pertussis toxin; Raf-1 SKELETAL MUSCLE IS WELL RECOGNIZED for its contribution to the regulation of plasma K ϩ concentration via insulin-, catecholamine-, and contraction-regulated Na ϩ -K
SKELETAL MUSCLE IS WELL RECOGNIZED for its contribution to the regulation of plasma K ϩ concentration via insulin-, catecholamine-, and contraction-regulated Na ϩ -K ϩ ATPase activity (4, 8, 20, 27) . Even during moderate exercise, however, total calculated K ϩ efflux can exceed the capacity of the sodium pump for K ϩ reuptake in rat muscle (9) . In addition, the complex kinetics of increased K ϩ reuptake by exercising muscle cannot be solely explained by simple stimulation of the sodium pump by the ion substrates (14) . There is accumulating evidence for additional inward K ϩ transport mechanisms in skeletal muscle (12, 21, 31) . We have reported that one of these mechanisms, bumetanide-sensitive Na
Ϫ cotransporter (NKCC) activity, contributes as much as one-third of the total inward K ϩ flux in skeletal muscle in response to catecholamines and contractile activity (12, 30, 31) . Thus skeletal muscle NKCC activity may contribute significantly to the regulation of plasma K ϩ concentration. We are just beginning to understand the intracellular signaling pathways that regulate NKCC activity in skeletal muscle. Understanding these mechanisms provides a broader perspective on the manner in which muscle responds to its environment. The isoproterenolstimulated cotransporter activity is dependent on mitogen-activated protein kinase kinase (MAPKK1/2, or MEK1/2) activity that stimulates extracellular signalregulated kinase 1 and 2 (ERK1/2) MAPK (12, 31) . The ␤-adrenergic agonist isoproterenol acts through receptors that couple to heterotrimeric GTP-binding proteins (G proteins, G␣␤␥) to elicit its effects (5, 32) . The activation of the ERK1/2 cascade has been established for G proteins of diverse classes, including stimulatory (G s ) and inhibitory (G i ) G proteins (22, 28) . In skeletal muscle, isoproterenol stimulates ␤ 2 -adrenergic receptors (␤ 2 -AR). Depending on cell type, it is thought that the ␤ 2 -AR can stimulate ERK MAPK by both G s and G i proteins (11, 18, 26) . In the case of G s , isoproterenol is reported to activate the ERK pathway through the cascade of adenylyl cyclase, protein kinase A (PKA), Raf, and MEK1/2 (10, 26) . There is also evidence for a ␤ 2 -AR-stimulated, pertussis toxin (PTX)-sensitive G i pathway (including also G o and G t family members) for stimulation of MAPKK1/2 and ERK1/2 MAPK through a Src, phosphatidylinositol 3-kinase (PI 3-K) 110␥/Ras/ Raf-1 complex (11, 28) . In addition to the linear pathways initiated either by G s or G i proteins, sequential activation of both G protein-coupled pathways has also been reported. Daaka et al. (11) describe a mechanism for a PKA-dependent switch of ␤ 2 -AR signaling from G s to G i to stimulate MAPK in HEK-293 cells. It is relevant, therefore, to wonder which mechanisms are involved in isoproterenol-stimulated, MAPK pathwaydependent NKCC activation in skeletal muscle. In particular, we were curious as to whether the mecha-nism exhibited phenotypic differences between slowtwitch and fast-twitch muscle.
In this study, we investigated whether inhibition of key components of putative ␤ 2 -AR-stimulated pathways affected isoproterenol-stimulated, MAPK pathway-dependent NKCC activity in skeletal muscle. Our results indicate that muscle fiber phenotype-dependent signaling involves both G s and G i proteins.
METHODS
Animal care and muscle preparation. Female SpragueDawley rats (100-150 g) were used for all experiments. The rats were housed in light-and temperature-controlled quarters where they received food and water ad libitum. Animals were randomly assigned to experimental groups, and all animals were handled identically. The rats were anesthetized with pentobarbital sodium (45 mg/kg ip) for tissue removal. Ankle extensor muscles, soleus (ϳ87% type I and 13% type II), and plantaris (ϳ9% type I and 91% type II) (3) were used for the experiments. Soleus and plantaris muscles were removed by careful dissection of the proximal tendons at the muscle origin and severing of the distal tendon. The muscles were placed in oxygenated Krebs-Ringer buffer at 25°C in preparation for further treatment (see below). The Animal Care and Use Committee of the University of Tennessee, Health Science Center, approved all procedures.
Materials. 86 RbCl was from New England Nuclear (Boston, MA). Isoproterenol, bumetanide, and horseradish peroxidase (HRP)-conjugated anti-mouse IgG were purchased from Sigma-Aldrich (St. Louis, MO). PTX and cholera toxin were obtained from List Biological Laboratories (Campbell, CA). Forskolin, 8-bromo-cAMP (8-BrcAMP), and H-89 were from CalBiochem (La Jolla, CA). GW5074 was from Tocris Cookson (Ellisville, MO). Phosphospecific antibody to ERK, anti-ERK-2, and anti-Raf-1 antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit phosphospecific Akt Ser 473 , anti-Akt, and anti-Raf-1 Ser 259 antibodies and HRP-conjugated anti-rabbit IgG antibody assay kits for MAPK and Akt activity were from New England Biolabs (Beverly, MA). Anti-Raf-1 Ser 338 antibody was from Upstate Biotechnology (Lake Placid, NY). Enhanced chemiluminescence (ECL) kit was from Amersham Life Sciences (Piscataway, NJ).
Muscle incubation and 86 Rb influx constant calculation. Each soleus and plantaris muscle was attached with 4-0 surgical silk suture to glass wands for rapid transfer among bathing solutions. The muscles were preincubated for 15 min at 30°C in preincubation medium [oxygenated Krebs-Ringer containing bumetanide (10 Ϫ5 M) or vehicle (DMSO) for the contralateral muscle]. For stimulation, muscles were taken directly to incubation medium (oxygenated Krebs-Ringer containing 1 Ci/ml 86 Rb and either bumetanide or vehicle) at 30°C, which contained 30 M isoproterenol, 0.5 mM 8-BrcAMP, 20 M forskolin, or 5 g/ml cholera toxin. Incubation was for 10 min. Muscles were immediately washed with ice-cold 0.9% saline solution. After being washed, the muscles were blotted, weighed, and homogenized in 2 ml of 0.3 M trichloroacetic acid (TCA). 86 Rb uptake by the muscle was measured by Cerenkov counting (Beckman LS 5000 TA). 86 Rb transport was expressed as a rate constant, as described previously (31) .
The mode of 86 Rb uptake, and phosphorylation and activation of protein kinases upon stimulation, were evaluated by adding inhibitors of intracellular signaling pathways. For specific inhibition of PKA, we preincubated the muscle with H-89 in concentration 2 M (7). To inhibit Raf-1 kinase, we preincubated the muscle with 1 M GW5074 (19) . To inhibit activation of PTX-sensitive G i/o/t proteins, rats weighing ϳ125 g were injected with PTX (6 g/rat ip) dissolved in sterile isotonic saline (0.5 ml) (24) . Control rats received the same amount of vehicle buffer as PTX-treated rats. At 30 h after PTX injection, muscles were dissected and 86 Rb transport was measured as described above.
NKCC activity. The bumetanide-sensitive 86 Rb uptake was used as an index of NKCC activity, as described previously (31) . The bumetanide-sensitive portion of 86 Rb uptake was calculated by subtracting the bumetanide treatment transport rate constant for the muscle of one hindlimb from the vehicle treatment rate constant of the contralateral muscle. Thus the bumetanide and vehicle treatments were statistically paired.
PKA assay. Skeletal muscle was excised from anesthetized rats and incubated for 25 min in oxygenated Krebs-Ringers solution. After incubation, the tissues were treated according to the protocol described by Keely et al. (17) . Briefly, after incubation, tissues were immediately frozen with Wollenberger tongs that had been cooled with liquid nitrogen. The muscles were pulverized in liquid nitrogen by using a percussion mortar, which had also been cooled with liquid nitrogen. The powder was stored at Ϫ80°C until use. The powdered tissue was suspended on ice in three times its weight of 10 mM potassium phosphate buffer containing 10 mM EDTA and 0.5 mM 1-methyl-3-isobutylxanthine, at pH 6.8, and homogenized with a Teflon pestle. The homogenate was immediately centrifuged at 12,000 g for 20 min at 4°C. The supernatant was diluted fivefold with the homogenization buffer. PKA activity was detected by using the PepTag Assay for nonradioactive detection of cAMP-dependent protein kinase activity (Promega). Briefly, 5 l of reaction buffer (100 mM Tris ⅐ HCl, 50 mM MgCl 2, and 5 mM ATP, pH 7.4), 5 l of PepTag A1 peptide (0.4 g/l kemptide), 5 l of activator solution (5 M cAMP, 100 M forskolin, or 2.5 mM 8-BrcAMP), and 5 l of deionized water were mixed on ice. The tubes were removed from the ice and incubated at 30°C for 1 min. Sample (5 l) was added to the tube and incubated at 30°C for 30 min. The reaction was stopped by placing the tube in a boiling water bath for 10 min. Eighty percent glycerol (1 l) was added to each sample, followed by electrophoresis on an 0.8% agarose gel (50 mM Tris ⅐ HCl, pH 8.0) for analysis. To block the activation of PKA, 5 l of H-89 (10 M) were substituted for the deionized water in the reaction mixture.
Immunoblotting. Whole muscle was preincubated and incubated as described for the 86 Rb assay. Incubation medium included no 86 Rb. After incubation with isoproterenol (as before), the muscles were placed in ice-cold lysis buffer (10 mM Tris ⅐ HCl, pH 7.4, 5 mM EDTA, 50 mM NaCl, 30 mM Na4P2O7, 50 mM NaF, 100 M Na3VO4, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 2 g/ml aprotinin, 2 g/ml leupeptin, 2 g/ml antipain, and 1 g/ml pepstatin A), homogenized with a Teflon pestle, and centrifuged at 4°C for 5 min at 5,000 g. The protein concentration of the supernatant was measured by the bicinchoninic acid assay (Pierce, Rockford, IL). Equal amounts of protein were mixed with SDS denaturing buffer, warmed to 95°C for 5 min, and electrophoresed on a 10% SDS-PAGE gel. The gels were electroblotted onto polyvinylidene difluoride membrane with the semidry blotter from Buchler Instruments (Fairfield, NJ). The membrane was incubated overnight at 4°C in the Western blocking buffer (1.5 mM NaH2PO4, 8 mM Na2HPO4, 0.15 M NaCl, and 0.5% Tween 100, pH 7.4) supplemented with 3% BSA. The membranes were then incubated at room temperature for 1.5 h in blocking buffer containing 1% BSA and the specific antibody (1:1,000). Phosphospecific antibodies to ERK1/2 dually phosphorylated on Thr 202 and Tyr 204 to Akt phosphorylated on Ser 473 were used to detect the catalytically activated forms of the kinases. Phosphospecific Raf-1 antibodies recognized Raf-1 phosphorylated only at Ser 259 or Ser 338 . The membranes were probed with HRPconjugated anti-rabbit or anti-mouse IgG for 1 h at room temperature, and immunoreactive proteins were detected by using ECL reagents. After determination of ERK1/2, Raf-1, or Akt phosphorylation, membranes were stripped for 30 min at 50°C, washed extensively, and used to determine total ERK1/2, Raf-1, or Akt protein expression with an appropriate antibody (1:1,000). Antibody signals were quantitated by video densitometry of film images of the blots. The extent of ERK or Akt phosphorylation was determined by comparing the amount of phosphorylated protein with the total ERK, Raf-1, or Akt expression, respectively.
Kinase assays for MAPK/ERK and Akt activity. The activity of MAPK and Akt was determined by using kinase assay kits from New England Biolabs. Homogenates of the muscles were prepared as described earlier. Supernatants of muscle lysates were mixed with immobilized phosphospecific p44/42 MAPK or Akt monoclonal antibody and incubated with gentle rocking overnight at 4°C. The beads were washed three times with ice-cold lysis and kinase buffers. The kinase assays were performed by incubating the suspended pellet in kinase buffer containing 200 m ATP and 2 g of Elk-1 or GSK-3 fusion protein for MAPK and Akt assays, respectively, for 30 min at 30°C. The samples were analyzed by 12% SDS-PAGE. Phospho-Elk-1-Ser 383 or phospho-glycogen synthase kinase-3-Ser 21/9 was detected with phosphospecific antibody (1:1,000 dilution) by using Western blot analysis.
Data analysis and statistics. Comparisons within and among treatments were made by analysis of variance. Differences between treatments were considered significant at P Ͻ 0.05. Data are reported as means Ϯ SE.
RESULTS

Involvement of G␣ s -stimulated PKA in regulation of NKCC activity.
As we have previously reported (12, 31) , isoproterenol activation of soleus and plantaris muscle ␤-AR stimulated bumetanide-sensitive 86 Rb uptake (Fig. 1A) ; bumetanide is a specific inhibitor of NKCC activity. It is well known that activation of PKA through a G␣ s -coupled mechanism is an important element for signal transduction by the ␤ 2 -AR, the predominant adrenergic receptor expressed in skeletal muscle (16) . Preincubation of the muscles with 2 M H-89, an inhibitor of PKA (7), abolished the isoproterenol-stimulated NKCC activity in both the soleus and plantaris muscles (Fig. 1A) . To determine whether PKA activation was sufficient to stimulate NKCC activity, we used three chemically and mechanistically different agents to activate PKA: cholera toxin, forskolin, and 8-BrcAMP. These agents significantly stimulated bumetanide-sensitive 86 Rb uptake only in the predominantly slow-twitch soleus muscle (Fig. 1B) . The increased NKCC activity caused by direct activation of PKA was sensitive to H-89 (not shown). However, the NKCC activity stimulated by the PKA activators was less than that stimulated by isoproterenol. To verify that these agents did indeed stimulate PKA activity in muscle, we performed an in vitro PKA assay using skeletal muscle lysates. Consistently, 8-BrcAMP, forskolin, and cAMP (as a control) stimulated PKA activity in whole muscle homogenates of both the soleus and plantaris muscles, and H-89 abolished this activity (Fig. 2) . These results indicate that PKA activation is necessary for ␤-AR-stimulated NKCC activity but appears to be only partially sufficient in the predominantly slow-twitch soleus muscle.
PTX sensitivity of stimulated NKCC activity. ␤ 2 -AR agonists can activate both G s -and G i -coupled mechanisms, and G s -stimulated PKA activity is required for the G i activation in some cell types (11, 26, 32) . These reports also emphasize that involvement of a PTXsensitive G i protein is a key step in the activation of the ERK1/2 MAPK cascade. Because isoproterenol-stimulated NKCC activity is MAPK dependent (12, 31) , it was of interest to examine the effect of PTX treatment on isoproterenol-stimulated NKCC activity. Thirty hours after injection of PTX into rats (48 g/kg body wt ip), isoproterenol-stimulated, NKCC-mediated 86 Rb uptake was abrogated in the soleus muscle but not in Fig. 1 . PKA activity was necessary, but not sufficient for, isoproterenol (Iso)-stimulated, bumetanide-sensitive 86 Rb uptake. A: inhibition of PKA activity with H-89 prevented the Iso-stimulation of Na ϩ -K ϩ -2Cl Ϫ (NKCC) activity. Muscles were preincubated with the PKA inhibitor H-89 for 15 min before Iso stimulation and during the 10 min of Iso-stimulated 86 Rb uptake. B: muscles stimulated with PKA-stimulating agents cholera toxin (CTX, 5 g/ml), forskolin (20 M), or 8-bromo-cAMP (8-BrcAMP) (0.5 mM) during the 10-min 86 Rb uptake period could not evoke maximal NKCC activation. Data are means Ϯ SE; n ϭ 6-8 muscle pairs per point. *, †P Ͻ 0.05 relative to the basal level and Iso-stimulated value in soleus muscle, respectively.
the plantaris muscle (Fig. 3) . Total isoproterenol-stimulated 86 Rb uptake decreased by the value of the bumetanide-sensitive portion (not shown). The portion of the NKCC activity that could be stimulated by 8-BrcAMP in the soleus muscle was not affected by the PTX treatment (Fig. 3) . PTX treatment affected neither total nor bumetanide-sensitive 86 Rb uptake in the unstimulated soleus and plantaris muscles (not shown).
PTX regulation of isoproterenol-mediated ERK1/2 activation. We have recently reported that inhibition of muscle MAPKK1/2 (MEK1/2) abolishes isoproterenolstimulated NKCC activity and ERK1/2 phosphorylation (31) . To investigate whether the PTX treatment that abolished isoproterenol-stimulated NKCC activity in soleus muscle (Fig. 3) affected ␤-AR-dependent ERK signaling pathways, we injected animals with PTX and assessed the ability of isoproterenol to activate ERK1/2. Isoproterenol stimulation of normal muscle resulted in a significant increase in ERK phosphorylation, with a greater extent observed in slow-twitch muscle (P Ͻ 0.05) (Fig. 4A) . Consistent with the ERK phosphorylation, ERK1/2 activity was also stimulated, as determined by in vitro kinase assay by using Elk-1 as the substrate (Fig. 4B) . PTX treatment prevented isoproterenol-stimulated ERK phosphorylation and activity in the soleus muscle but not in the plantaris muscle (Fig. 4) . PTX treatment did not change the basal level of ERK phosphorylation, ERK activity, or 86 Rb uptake by the soleus muscle. PTX was injected into rats 30 h before the ex vivo experiments. The NKCC stimulators Iso and 8-BrcAMP were added during the 10-min 86 Rb uptake period. PTX treatment abrogated the Iso-stimulated NKCC activity but did not affect the 8-BrcAMP-mediated NKCC activity in soleus muscle. Data are means Ϯ SE; n ϭ 10 muscle pairs per point. *, †P Ͻ 0.05 relative to the basal level and Iso-stimulated value in soleus muscle, respectively. After treatment, muscles were immediately clamp frozen with liquid nitrogen and homogenized. A: equal amounts of protein (25 g) were used for Western blot analysis with a phosphospecific ERK1/2 antibody, followed by stripping and reprobing with an anti-ERK-2 antibody. Data are the densitometric ratio of phospho-ERK to total ERK normalized to the basal mean value (taken as 1.0). B: an in vitro kinase assay was performed as described in METHODS, and phosphorylated Elk-1 substrate was detected by immunoblotting with phosphospecific Elk-1 antibody. Data are the densitometric ratio of phospho-Elk-1 to total ERK normalized to the basal mean value (taken as 1.0). Representative blots are shown. Data are means Ϯ SE of 6 muscles. *, †P Ͻ 0.05 relative to the basal and Iso-stimulated ERK activity in the soleus muscle, respectively. total ERK protein expression in either soleus or plantaris muscles (not shown).
To establish whether PTX treatment affected ERK activation through modulation of Raf-1, we measured Raf-1 phosphorylation on Ser 338 and Ser 259 . Phosphorylation of Raf-1 on Ser 338 activates Raf-1 (23, 25, 31) . Raf-1 activation is required for ERK stimulation (18) . In contrast, Raf-1 phosphorylation on Ser 259 inhibits kinase activity by attracting protein 14-3-3 (18) . Therefore, one measure of the activation of Raf-1 is the relative degree of phosphorylation on these residues. Stimulation of the soleus muscle with isoproterenol induced a 6.5-fold increase in the Raf-1 phosphorylation on Ser 338 , whereas plantaris muscle exhibited a weak (1.5-fold over basal level) enhancement of Raf-1 phosphorylation (Fig. 5) . PTX treatment, shown in Fig.  4 to inhibit ERK phosphorylation, did not alter isoproterenol-induced Raf-1 phosphorylation on Ser 338 or Raf-1 expression (Fig. 5) . The kinase activity of Raf-1 declines with phosphorylation on Ser 259 . Stimulation of the muscles with isoproterenol nearly doubled the level of Raf-1 phosphorylation Ser 259 in the soleus muscle and nearly tripled the level of Ser 259 phosphorylation in the plantaris muscle (Fig. 6) . Remarkably, the inhibition of PTX-sensitive G proteins led to a robust eightfold increase in the inhibitory Raf-1 phosphorylation on Ser 259 in the isoproterenol-stimulated soleus muscle (Fig. 6) . PTX alone did not change the extent of Raf-1 Ser 259 phosphorylation (Fig. 6 ). Recent studies have identified a negative regulatory role for protein kinase B/Akt in ERK MAPK pathway activation (25, 33) . A well-recognized possibility for ERK inhibition is via Akt-dependent Raf-1 phosphorylation on Ser
259
. To establish whether PTX treatment affected ERK activation through Akt modulation, we examined the Akt activation by assessing the phosphorylation of Akt on Ser 473 and Akt kinase activity. Isoproterenol alone did not significantly change either Akt Ser 473 phosphorylation or Akt activity in the soleus muscle (Fig. 7) or plantaris muscle (not shown). Akt activity was measured by in vitro kinase assay by using GSK-3 as the substrate. PTX treatment increased Akt phosphorylation on Ser 473 1.5-fold in isoproterenol-stimulated soleus muscle, coincident with stimulation of Akt activity (Fig. 7) . It is noteworthy that, in addition to increased isoproterenol-stimulated phosphorylation, Akt expression was 1.5-fold greater in the soleus muscle of PTX-treated rats (Fig. 7) . Taken together, these data indicate that PTX may inhibit isoproterenol-stimulated ERK1/2 phosphorylation in the soleus muscle by Akt-mediated suppression of Raf-1 activity. Thus it appears that Raf-1 may act as a central control point for NKCC activation in the soleus muscle. If so, inhibition of Raf-1 should suppress isoproterenol-stimulated NKCC activity. GW5074, a potent Raf-1 kinase inhibitor (19) , abolished the isoproterenol-stimulated NKCC activity in the soleus muscle (Fig. 8) . Isoproterenol-stimulated NKCC activity in the plantaris muscle was not affected by GW5074 treatment (Fig. 8) . A summary schematic of the proposed mechanism is shown in Fig. 9 . (1) and striated muscles (2, 12, 31) . was not PTX sensitive. Soleus and plantaris muscles were incubated as described in METHODS. The supernatants of muscle lysates (100 g of protein) were subjected to SDS-PAGE and immunoblotted with an anti-phospho-Ser 338 Raf-1 antibody, followed by stripping and reprobing the blots with an anti-total Raf-1 antibody. Plotted data are the densitometric ratio of phospho-Raf-1 to total Raf-1 normalized to the basal mean value (taken as 1.0). Iso increased the phosphorylation of Raf-1 on Ser 338 to a greater extent in the soleus muscle. PTX treatment did not affect the increase in Raf-1 phosphorylation. Data are means Ϯ SE of 6 muscles. *P Ͻ 0.05 relative to the basal value of Raf-1 phosphorylation on Ser 338 . Fig. 6 . Effect of PTX treatment on Raf-1 phosphorylation on Ser 259 . Soleus and plantaris muscles were incubated as described in Fig. 5 . The supernatants of muscle lysates (100 g of protein) were subjected to SDS-PAGE and immunoblotted with an anti-phosphoSer 259 Raf-1, followed by stripping and reprobing the blots with anti-total Raf-1 antibody (representative blots are shown on Fig. 5 ). Plotted data are the densitometric ratio of phospho-Raf-1 to total Raf-1 normalized to the basal mean value (taken as 1.0). Iso increased the phosphorylation of Raf-1 on Ser 259 to a greater extent in the plantaris muscle. Unlike the plantaris muscle, PTX treatment resulted in a robust increase of Raf-1 inhibition in the Iso-treated soleus muscle. Data are means Ϯ SE of 6 muscles. *, †P Ͻ 0.05 relative to the basal and Iso-stimulated level of Raf-1 phosphorylation on Ser 259 , respectively.
In addition, it has been shown that stimulation of NKCC activity is MAPK dependent in striated muscle (2, 31) . The present study demonstrates that ␤-AR stimulation can activate fiber phenotype-specific signaling cascades that involve both G s -and G i -coupled processes. Furthermore, the data indicate that the G i -coupled signals may suppress an Akt pathway that inhibits Raf-1 activation upstream of ERK1/2 MAPK. We discuss below the dual G protein-coupled signaling mechanisms that appear to be involved in the regulation of skeletal muscle NKCC activity.
It is well established that one consequence of ␤-AR activation is the dissociation of the G␣ s subunit from the heterotrimeric G protein complex, with subsequent activation of adenylyl cyclase and production of cAMP. cAMP can activate PKA by causing dissociation of the were subjected to SDS-PAGE and immunoblotted with an anti-phospho-Ser 473 Akt antibody, followed by stripping and reprobing the blots with an anti-total Akt antibody. Data are the densitometric ratio of phosphoAkt to total Akt normalized to the basal mean value (taken as 1.0). B: phosphorylation of GSK-3, an Akt substrate, on Ser 9/21 was used to determine Akt activity. Plotted data are the densitometric ratio of phospho-Akt to total Akt normalized to the basal mean value (taken as 1.0). Representative blots are shown. These results demonstrate that PTX provoked a significant increase in Akt phosphorylation and activity in Iso-stimulated soleus muscle. Data are means Ϯ SE of 6 muscles. *, †P Ͻ 0.05 relative to the basal and Iso-stimulated level of Akt activation, respectively. Fig. 8 . A specific inhibitor of Raf-1 kinase activity, compound GW5074, abrogated Iso-stimulated bumetanide-sensitive 86 Rb uptake in the soleus muscle. Muscles were preincubated with the Raf-1 kinase inhibitor GW5074 for 15 min before Iso stimulation and during the 10 min of Iso-stimulated 86 Rb uptake. Iso stimulation of bumetanide-sensitive 86 Rb uptake in the plantaris muscle was not affected by GW5074 treatment. Data are means Ϯ SE; n ϭ 4-15 muscle pairs per point. *, †P Ͻ 0.05 relative to the basal and Isostimulated value, respectively. Fig. 9 . Schematic summary of muscle phenotype differences in the Iso-stimulated NKCC activity. Data presented here and previously (12, 31) indicate regulation of the ERK MAPK pathway through Gsand Gi-coupled processes in the soleus muscle. Points of pharmacological inhibition are indicated with a circled cross. Feasible pathways not excluded by the data are marked as dashed arrows. ␤-AR, ␤-adrenergic receptor.
inhibitory subunit from the catalytic subunit. Our data show that H-89, an inhibitor of PKA, abolished isoproterenol-stimulated NKCC activity (Fig. 1A) . Whether PKA stimulation was also sufficient for NKCC stimulation was addressed by stimulation of PKA activity independent of the ␤-AR G protein-coupled mechanism. NKCC activity was stimulated only in the predominantly slow-twitch soleus muscle (Fig. 1B) . Phenotype differences in ␤-AR-stimulated PKA pathway components have been noted previously. In rat skeletal muscle, ␤-AR density significantly correlates with muscle oxidative capacity (16, 29) . Moreover, isoproterenol-stimulated adenylyl cyclase activity is considerably greater in slow-twitch oxidative muscle (29) . In agreement, Hoover et al. (15) showed that the slowtwitch soleus muscle expresses twice the PKA catalytic activity as fast-twitch muscle. Furthermore, isoproterenol-mediated ERK1/2 MAPK activation was significantly greater in the soleus muscle than in the plantaris muscle (Fig. 4) , which may reflect phenotyperelated differences in ERK expression (12) . Thus clear phenotypic differences are evident in the expression and activity of the ␤-AR, PKA, and ERK MAPK, and likely many other phenotypic differences in signal pathways exist. As an example, despite the necessity for PKA activation for NKCC activity in both the soleus and plantaris muscles, PKA activation through receptor-independent pathways was partially sufficient for NKCC activation only in the slow-twitch soleus muscle (Figs. 1 and 3) . Cholera toxin (which stimulates G␣ s activity), forskolin (which upregulates adenylyl cyclase), and 8-BrcAMP were unable to completely mimic the isoproterenol-stimulated NKCC activity (Fig. 1B) . Although the evidence that PKA-stimulating agents cannot mimic the effects of isoproterenol on ERK MAPK is not new (10), we raise several possibilities that could explain the incomplete NKCC activation by the PKA stimulators. It is entirely possible that ␤-AR activation stimulates covalent modification of PKA, in addition to the allosteric activation of PKA by cAMP. Indeed, phosphatidylinositol 3,4,5-trisphosphate (PIP 3 )-dependent phosphoinositide-dependent protein kinase-1 (PDK-1) activity has been implicated in the phosphorylation of Thr 197 in the activation loop of the PKA catalytic subunit (6) . Our recent results provide support for this possibility. Inhibition of PI 3-K, which produces PIP 3 , decreases both isoproterenol-stimulated ERK1/2 phosphorylation and NKCC-mediated transport by half in the soleus muscle (12) . Another possibility is simply a physically incomplete activation of PKA by the PKA activators, although it is curious that all three mechanistically and chemically dissimilar compounds produced strikingly similar results (Fig.  1B ). Yet another possibility, and one which the data here support, is that additional pathways participate in regulation of ERK-dependent NKCC activity in the soleus muscle, as discussed below.
PTX treatment abolished isoproterenol-mediated ERK phosphorylation and NKCC activation in the soleus muscle but not in the plantaris muscle. PTX causes ADP ribosylation of the heterotrimeric G i/o/t proteins, thereby preventing receptor-mediated dissociation of G␣␤␥ subunits. Both G␣ i and G␤␥ are known to activate Raf-1 and, subsequently, the ERK cascade (11, 13, 28) . The data for the soleus muscle consistently show the necessity of active G i proteins to stimulate the Raf-1/ERK MAPK pathway, in addition to a G s mechanism. Whereas isoproterenol can activate Raf-1 through a PTX-insensitive phosphorylation on Ser 338 , active G␣ i/o/t subunits are required to prevent hyperphosphorylation of Raf-1 on Ser 259 , a modification that inhibits Raf-1 kinase activity. Recently, Daaka et al. (11) suggested a switching mechanism for ERK activation by which G␣ s -mediated activation of PKA is required for activation of PTX-sensitive G␣ i/o/t proteins and, subsequently, the ERK MAPK cascade. However, neither 8-BrcAMP-induced stimulation of NKCC activity nor isoproterenol-stimulated phosphorylation (activating) of Raf-1 on Ser 338 were PTX sensitive (Figs. 3  and 5 ). It appears that parallel pathways, PTX-insensitive and PTX-sensitive, activate NKCC in the soleus muscle (Fig. 9) . Taken together, our findings corroborate previous evidence that direct activation of ␤-AR is necessary for the complete cascade of signaling events. Furthermore, we propose that activation of PTX-sensitive proteins is a prerequisite for suppression of inhibitory inputs on the ERK MAPK pathway and NKCC activity. Support for the inhibitory influence on the Raf-1/ERK MAPK pathway comes from our recent data that demonstrate an Akt-dependent inhibition of the ERK cascade (and thus NKCC activity) (12) . It has been shown that active Akt markedly inhibits Raf-1 activity by inducing the phosphorylation of Raf-1 on Ser
, preventing ERK activation (33) . Akt activity was increased, and inhibition of Raf-1 prevailed in the PTX-treated soleus muscle (Fig. 5) . This was accompanied by the inability to stimulate ERK1/2 and NKCC activity (Figs. 3 and 4) .
On the basis of these data, we propose that G smediated PKA activity is necessary, but not fully sufficient, for maximal ␤-AR-mediated stimulation of MAPK pathway-dependent NKCC in skeletal muscle. In addition to PKA activation, ␤-AR activation in the soleus muscle apparently prevents activation of Akt through PTX-sensitive G i/o/t proteins (Figs. 7 and 9 ). Active Akt can suppress Raf-1/ERK MAPK pathway stimulation and subsequent NKCC activity. In the predominantly fast-twitch plantaris muscle, PTX-sensitive mechanisms are not involved in the regulation of MAPK pathway-dependent NKCC. Together, these data demonstrate not only fundamental differences between fast-and slow-twitch phenotypes for controlling K ϩ transport but also broader implications for differences in signaling that may be important in muscle plasticity and disease.
